Disclaimer:
This blog is for informational purposes only and should not be taken as medical advice. Content is sourced from third parties, and we do not guarantee accuracy or accept any liability for its use. Always consult a qualified healthcare professional for medical guidance.
Melanoma is an aggressive skin cancer from melanocytes, pigment-producing cells. Types include superficial spreading (70%), nodular (15-20%), lentigo maligna (10%), and acral lentiginous (rare, palms/soles). Stages I-IV, with thickness (Breslow) and ulceration key for prognosis. In 2025, ~100,000 US cases, rising due to UV exposure, with higher incidence in fair-skinned individuals.
Symptoms include new/changing moles (asymmetrical, irregular borders, varied colors, diameter >6mm, evolving), itching, bleeding, or ulceration. Advanced causes lumps, swollen nodes, or metastatic symptoms (cough, pain). ABCDE rule aids detection.
UV radiation (sun/tanning beds) is primary, causing DNA damage. Risk factors include fair skin, freckles, many moles, family history, immunosuppression, and BRAF mutations (50%). In 2025, genomics show NRAS/KIT in non-UV types.
Diagnosis uses dermoscopy, biopsy (excisional for depth), sentinel node biopsy for staging, and imaging (PET/CT) for metastases. Molecular testing for BRAF/NRAS. In 2025, AI dermoscopy detects 95% of melanomas.
Early-stage uses excision with margins. Stage III-IV adds immunotherapy (pembrolizumab, nivolumab), targeted therapy (BRAF/MEK inhibitors), or surgery. In 2025, tebentafusp and TIL therapy improve survival.
In 2025, 5-year survival is 99% localized, 35% metastatic. Immunotherapy raises metastatic to 50%. By 2030, vaccines and AI could achieve 60% metastatic survival.
Mayo Clinic’s “Melanoma – Symptoms and causes” for symptoms; Cleveland Clinic’s “Melanoma: Symptoms, Stages, Diagnosis, Treatment & Prevention” for treatment; NCI’s “Melanoma Treatment” for prognosis; PMC’s “Melanoma: An Overview” for overview; OncoDaily’s “Melanoma: Symptoms, Diagnosis, Treatment” for details; Skin Cancer Foundation’s “Melanoma” for prevention; Cancer Research UK’s “Melanoma skin cancer” for research; American Cancer Society’s “Melanoma Skin Cancer” for statistics; WebMD’s “Melanoma Skin Cancer” for symptoms; Healthline’s “Melanoma: Pictures, Stages, Treatment, Survival Rates” for outlook.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
1. Scan at your preferred center.
2. Written report from a specialist radiologist sent via email.
3. Access and download your scan images digitally.
4. Upon request, we can send the report and images to your doctor or hospital.
5. For self-referred patients, there is an additional charge of £30, which includes scan referral and a discussion with a private GP before and after the scan